drugset / Trial / NCT06615570

A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants

NCT06615570

Phase 1 Completed 30 enrolled Vertex Pharmaceuticals Incorporated
RandomizedSequentialQuadruple-blindTreatment

Summary

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of VX-973 in healthy participants.

Timeline

Start
2024-09-30
Primary completion
2025-07-21
Completion
2025-07-21

Drugs

EvaluationDrugModalityDoseRoute
Subject VX-973 Unknown Oral

Indications

No indication recorded.